Johnson & Johnson Profit Margin 2010-2023 | JNJ

Current and historical gross margin, operating margin and net profit margin for Johnson & Johnson (JNJ) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Johnson & Johnson net profit margin as of December 31, 2023 is 37.79%.
Johnson & Johnson Annual Profit Margins
Johnson & Johnson Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $376.859B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $742.415B 123.74
Novo Nordisk (NVO) Denmark $556.499B 45.85
Merck (MRK) United States $323.823B 85.19
AbbVie (ABBV) United States $319.482B 15.98
Novartis AG (NVS) Switzerland $212.363B 14.71
AstraZeneca (AZN) United Kingdom $199.261B 17.66
Pfizer (PFE) United States $155.954B 15.09
Sanofi (SNY) $116.816B 10.52
Innoviva (INVA) United States $1.016B 9.17